TD Private Client Wealth LLC Decreases Stock Position in Danaher Corporation $DHR

Key Points

• TD Private Client Wealth LLC reduced its stake in Danaher Corporation by 40.8% during the 2nd quarter, now holding 8,200 shares valued at $1,620,000.
• Other institutional investors, such as Vanguard Group and Price T Rowe Associates, have increased their holdings, with Vanguard owning over 59 million shares worth approximately $12.3 billion.
• Danaher Corporation recently announced a quarterly dividend of $0.32 per share, with an annualized yield of 0.7% and a payout ratio of 27.23%.

TD Private Client Wealth LLC decreased its position in Danaher Corporation (NYSE:DHR - Free Report) by 40.8% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,200 shares of the conglomerate's stock after selling 5,647 shares during the quarter. TD Private Client Wealth LLC's holdings in Danaher were worth $1,620,000 at the end of the most recent quarter.

Other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. boosted its position in Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock valued at $12,296,123,000 after buying an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after acquiring an additional 612,154 shares in the last quarter. Bank of New York Mellon Corp boosted its holdings in Danaher by 2.3% in the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock valued at $1,800,614,000 after purchasing an additional 194,466 shares during the last quarter. Invesco Ltd. grew its stake in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate's stock valued at $965,259,000 after purchasing an additional 1,450,703 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate's stock worth $867,168,000 after purchasing an additional 163,332 shares during the last quarter. 79.05% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Danaher

In related news, Director Teri List sold 2,778 shares of the stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $211.06, for a total value of $586,324.68. Following the sale, the director owned 20,751 shares of the company's stock, valued at $4,379,706.06. This trade represents a 11.81% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 11.10% of the company's stock.

Danaher Stock Performance

Shares of NYSE DHR opened at $181.56 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The firm's 50-day moving average price is $199.54 and its two-hundred day moving average price is $197.72. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $279.90. The stock has a market capitalization of $130.01 billion, a P/E ratio of 38.63, a P/E/G ratio of 2.65 and a beta of 0.75.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.64 by $0.16. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business had revenue of $5.94 billion for the quarter, compared to analysts' expectations of $5.83 billion. During the same period in the prior year, the firm earned $1.72 EPS. The business's quarterly revenue was up 3.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. As a group, sell-side analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be issued a dividend of $0.32 per share. The ex-dividend date of this dividend is Friday, September 26th. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. Danaher's payout ratio is 27.23%.

Wall Street Analyst Weigh In

Several research firms have recently commented on DHR. Scotiabank upgraded Danaher from a "sector perform" rating to a "sector outperform" rating and set a $275.00 target price for the company in a research note on Friday, July 11th. Evercore ISI decreased their price objective on shares of Danaher from $230.00 to $226.00 and set an "outperform" rating for the company in a report on Tuesday, July 8th. Robert W. Baird boosted their target price on shares of Danaher from $225.00 to $226.00 and gave the stock an "outperform" rating in a research report on Friday, July 18th. Bank of America reduced their price target on shares of Danaher from $230.00 to $220.00 and set a "buy" rating on the stock in a research report on Monday. Finally, UBS Group lowered their price objective on Danaher from $240.00 to $225.00 and set a "buy" rating for the company in a report on Wednesday, July 23rd. Seventeen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $245.91.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.